Poznan University of Medical Sciences
ump.edu.plTotal trials
143
Active
38
Phase 3
2
Total enrollment
30,636
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 39 of 39 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ropivacaine 0.2% Injectable Solution | — | — | — | — | 14 | ||
| Dexmedetomidine | — | — | — | — | 11 | ||
| Dexamethasone 4mg | — | — | — | — | 7 | ||
| 0.9%NaCl | — | — | — | — | 6 | ||
| perineural Dexamethasone | — | — | — | — | — | 2 | |
| intravenous Dexamethasone | — | — | — | — | — | 2 | |
| Ropivacaine 0.5% Injectable Solution | — | — | — | — | — | 2 | |
| Fluoxetine | — | — | — | — | — | 1 | |
| Escitalopram | — | — | — | — | — | 1 | |
| Sertralin | — | — | — | — | — | 1 | |
| Ropivacaine 0.2% for PENG Block | — | — | — | — | — | 1 | |
| Ropivacaine 0.2% for LFCB | — | — | — | — | — | 1 | |
| Ropivacaine 0.2% for L-ESPB | — | — | — | — | — | 1 | |
| Ropivacaine 0.2% for S-ESPB | — | — | — | — | — | 1 | |
| 0.2ml/kg 0.2% ropivacaine | — | — | — | — | — | 1 | |
| Allopurinol 200 mg | — | — | — | — | — | 1 | |
| Optional intervention | — | — | — | — | — | 1 | |
| Sunecos-200 Injectable Hyaluronic acid and amino acids solution | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | — | 8 | ||
| sodium Chloride | — | — | — | — | — | 2 | |
| Sodium Chloride 0.9% Inj | — | — | — | — | 3 | ||
| 0.2% ropivacaine | — | — | — | — | 2 | ||
| Dexamethasone 8mg | — | — | — | — | — | 1 | |
| Tranexamic Acid Bolus Plus | — | — | — | — | — | 1 | |
| Tranexamic Acid Bolus Only | — | — | — | — | — | 1 | |
| Intrathecal Morphine | — | — | — | — | — | 1 | |
| Ropivacaine Hydrocloride | — | — | — | — | — | 1 | |
| Ropivacaine 0.2% for Interscalene Block | — | — | — | — | — | 1 | |
| Ropivacaine 0.2% for Infraclavicular and Suprascapular Nerve Blocks | — | — | — | — | — | 1 | |
| sham block with 0.9% sodium chloride | — | — | — | — | — | 1 | |
| Dexamethasone + Dexmedetomidine | — | — | — | — | — | 1 | |
| iv dexamethasone | — | — | — | — | — | 1 | |
| pn dexamethasone | — | — | — | — | — | 1 | |
| Patients requiring cefotaxime treatment | — | — | — | — | — | 1 | |
| Patients requiring meropenem treatment | — | — | — | — | — | 1 | |
| Patients requiring fluconazole treatment | — | — | — | — | — | 1 | |
| Patients requiring isavuconazole treatment | — | — | — | — | — | 1 | |
| Patients requiring anidulafungin treatment | — | — | — | — | — | 1 | |
| chemotherapy according to Stupp protocol | — | — | — | — | — | 1 |
Next readouts
- 2025-06-30
- 2025-12-19
- 2026-05-01
- 2026-05-30
- 2026-05-30
- 2026-05-31
- 2026-07-31
- 2026-09-30
- 2026-09-30
- 2026-12-30
Top conditions
- Hip Osteoarthritis18
- Knee Osteoarthritis11
- Hip Arthropathy10
- Hip Pain Chronic9
- Knee Pain Chronic9
- Obesity7
- Knee Arthritis6
- Scoliosis Idiopathic5
Frequently asked questions about Poznan University of Medical Sciences
- How many clinical trials does Poznan University of Medical Sciences have on ClinicalTrials.gov?
- Poznan University of Medical Sciences is listed as the lead sponsor on 143 clinical trials in ClinicalTrials.gov, 38 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Poznan University of Medical Sciences's trials are in Phase 3?
- 2 of Poznan University of Medical Sciences's trials are in Phase 3, spread across 39 active drug programs.
- What therapeutic areas does Poznan University of Medical Sciences focus on?
- Poznan University of Medical Sciences's most-studied conditions on ClinicalTrials.gov are Hip Osteoarthritis, Knee Osteoarthritis, Hip Arthropathy, Hip Pain Chronic, Knee Pain Chronic.
- When are Poznan University of Medical Sciences's next clinical trial readouts?
- Poznan University of Medical Sciences has 10 upcoming primary-completion readouts tracked here; the soonest is “Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.”, expected around 2025-06-30.